Actively Recruiting

Phase 4
Age: 22Years - 65Years
MALE
ID05383274

Optilume PoST AppRoval Clinical Evaluation of Andrology ParaMeters

Led by Urotronic Inc. · Updated on 2026-04-28

34

Participants Needed

9

Research Sites

26 weeks

Total Duration

On this page

Sponsors

U

Urotronic Inc.

Lead Sponsor

L

Laborie Medical Technologies Inc.

Collaborating Sponsor

AI-Summary

What this Trial Is About

This research evaluates semen quality after treatment with the Optilume Urethral Drug Coated Balloon (DCB) in men aged 22 to 65 who have an anterior urethral stricture treatable with this device. It is a single-arm, prospective study involving 34 male participants across multiple sites in the United States. The study aims to assess various urinary and sexual function outcomes following treatment. Participants receive the Optilume Urethral DCB, a catheter with a balloon coated with the drug paclitaxel that transfers the medication to the urethral wall upon inflation. The study includes follow-up visits at 30 days, 3 months, 6 months, and 12 months after treatment to monitor symptoms and function. Semen quality is tested before treatment and at 3 and 6 months post-treatment, with additional testing up to 12 months if abnormalities are detected. During the study, participants undergo evaluations of urinary symptoms, sexual function, and voiding function at scheduled intervals. Semen samples are collected to assess sperm characteristics. Safety endpoints are reviewed at 3 and 6 months. Follow-up continues for up to a year or longer if semen abnormalities persist, ensuring comprehensive monitoring of treatment effects and participant well-being.

CONDITIONS

Brief Title

Optilume PoST AppRoval Clinical Evaluation of Andrology ParaMeters

Who Can Participate

Age: 22Years - 65Years
MALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Male subjects between 22 and 65 years of age
  • Diagnosed with a stricture in the anterior urethra treatable with the Optilume Urethral DCB
  • Willing to provide written informed consent and comply with follow-up assessments
  • Able to provide viable semen samples with baseline quality above reference values including total sperm ≥39 million, concentration ≥15 million/mL, total motility ≥40%, progressive motility ≥32%, and morphology ≥4%
Not Eligible

You will not qualify if you...

  • Known hypersensitivity to paclitaxel or related compounds
  • History of vasectomy or conditions that inhibit semen or sperm production or ejaculatory function
  • Currently taking certain medications like 5-alpha reductase inhibitors, alpha-blockers, SSRIs, or hormone therapy without proper washout
  • Unwilling to abstain or use a condom for 30 days after the procedure
  • Unwilling to use highly effective contraception for 6 months if partner could become pregnant
  • History of cancer not in complete remission

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - Single procedure with follow-up assessments up to 12 months

Participants receive the Optilume Urethral Drug Coated Balloon (DCB) treatment for their anterior urethral stricture.

1 treatment visit and follow-up visits at 30 days, 3 months, 6 months, and 12 months post-treatment

Post-treatment Follow-up

Duration - Up to 12 months post-treatment with periodic assessments thereafter if needed

Participants are monitored for Lower Urinary Tract Symptoms, sexual function, voiding function, and semen quality at specified intervals. Additional semen quality assessments occur if abnormalities are detected at 6 months.

Follow-up visits at 30 days, 3 months, 6 months, 12 months, and additional visits as needed for semen quality monitoring

Trial Site Locations

Total: 9 locations

1

Arkansas Urology

Little Rock, Arkansas, United States, 72211

Actively Recruiting

2

Orlando Health

Orlando, Florida, United States, 32806

Actively Recruiting

3

Florida Urology

Tampa, Florida, United States, 33615

Actively Recruiting

4

Regional Urology

Shreveport, Louisiana, United States, 71106

Completed

5

Chesapeake

Hanover, Maryland, United States, 21076

Completed

6

Freedman Urology

Las Vegas, Nevada, United States, 89144

Actively Recruiting

7

New Jersey Urolgy

Millburn, New Jersey, United States, 07041

Completed

8

Western New York

Cheektowaga, New York, United States, 14225

Actively Recruiting

9

Urology Clinics of North Texas

Dallas, Texas, United States, 75231

Actively Recruiting

Loading map...

Research Team

B

Brenda Johnson, MS

R

Reem Ennenga

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Similar Trials

9000 URETHRA STUDY: a Prospective, Observational Study About...

Urethral Stricture

Actively Recruiting

2 locations

Multi-stage Urethroplasty with Dorsal Graft Inlay Comparing ...

Urethra Stenosis

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here